Slide 1: Q3 2025 Earnings Presentation
Q3 2025 Earnings Earnings Presentation October 29, 2025
Slide 2: Disclaimer
Disclaimer Forward-looking statements Non-GAAP financial measures This presentation contains forward-looking statements within the meaning of Section To evaluate our performance, we monitor a number of key indicators at the 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Slide 3: Key observations to date
Key observations to date Avantor is a critical partner and has incredible customer reach Solid and growing portfolio of products and services Confident in the long-term trajectory of the end markets we serve Dedicated global team of associates unified in commitment to drive growth Organizational com
Slide 4: Q3 2025 performance highlights
Q3 2025 performance highlights Laboratory Solutions: • Continued end market uncertainty related to basic research funding Reported Adjusted Revenue1 EBITDA margin Bioscience Production: $1.62B 16.5% • Operational headwinds continue to impact throughput Other Highlights: Adjusted • On track to delive
Slide 5: Q3'25 financial results
Q3’25 financial results Q3’25 Q3’24 Reported revenue $1,624M $1,714M Organic growth -5% -1% Adj. gross profit $527M $573M % of revenues 32.4% 33.4% Adj. EBITDA $268M $303M % of revenues 16.5% 17.6% Adj. operating income $237M $275M % of revenues 14.6% 16.0% Adj. earnings per share $0.22 $0.26 Free c
Slide 6: Q3'25 performance by segment
Q3’25 performance by segment Laboratory Solutions Bioscience Production Reported Adjusted Reported Adjusted Revenue Operating income Revenue Operating income $1,097M $124M $527M $128M Adjusted Adjusted Organic Growth: -5% Operating 11.3% Organic Growth: -4% Operating 24.2% Margin: Margin: Note: Page
Slide 7: 2025 full-year guidance
2025 full-year guidance1,2 FY 2025 guidance FY 2025 guidance Metric (updated 8/01/25) (current) Organic Revenue -2.0% to +0% -3.5% to –2.5% Growth Adj. EBITDA 16.5% to 17.0% Mid-16’s% Margin Adj. EPS3 $0.94 to $0.98 $0.88 to $0.92 Free Cash $550 to $600M $550 to $600M Flow4 1For reconciliation from
Slide 8: Avantor Revival
Avantor Revival Five initial pillars: • Evolve our go-to-market approach • Strategically invest in our manufacturing and supply chain organization • Scrutinize our portfolio to ensure a focus on our core business • Simplify operating processes and remove internal barriers • Strengthen our talent and
Slide 9: Powering science at every step.
Powering science at every step. €\f avantor’
Slide 10: Appendix
10 Appendix avantor
Slide 11: Clinical Services divestiture impact
Clinical Services divestiture impact1,2,3 THIRD QUARTER IMPACT ~$48M ~$15M ~$0.01 ~$7M Reported revenue Adjusted EBITDA Adjusted EPS Free cash flow headwind headwind dilution headwind Reported YoY Growth Adj. EBITDA Margin Net Interest Expense Headwind ~2.8% Headwind ~40bps Reduction $7M FULL YEAR I